Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia. by Molano, M et al.
ORIGINAL ARTICLE
Prevalence and determinants of Chlamydia trachomatis
infections in women from Bogota, Colombia
M Molano, E Weiderpass, H Posso, S A Morre´, M Ronderos, S Franceschi, A Arslan, C J L M Meijer,
N Mun˜oz, A J C van den Brule, and the HPV Study Group*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Elisabete Weiderpass, Unit
of Field and Intervention
Studies, International
Agency for Research on
Cancer, 150 cours Albert
Thomas, F-69372 Lyon
Cedex 08, France;
weiderpass@iarc.fr
Accepted for publication
11 June 2003
. . . . . . . . . . . . . . . . . . . . . . .
Sex Transm Infect 2003;79:474–478
Objectives: Chlamydia trachomatis infection in the cervix and uterus has been hypothesised to be a co-
factor for cervical cancer. We performed a cross sectional study in Bogota, Colombia, where cervical
cancer rates are high, to determine the prevalence and determinants of C trachomatis infection, and in
particular its association with human papillomavirus (HPV).
Methods: 1829 low income sexually active women were interviewed and tested for C trachomatis, using
an endogenous plasmid PCR-EIA, and for 37 HPV types, using a general primer GP5+/6+ mediated PCR-
EIA.
Results: The overall prevalence of C trachomatis was 5.0%, and it did not differ substantially between
women with normal (5.0%) and those with abnormal (5.2%) cervical cytology. Women infected with any
HPV type (15.1%) had a slightly increased risk of being simultaneously infected with C trachomatis
(adjusted OR 1.3, 95% CI: 0.8 to 2.4). This association was stronger when multiple HPV infections
(adjusted OR 2.5, 95% CI: 1.1 to 5.9) were present. No other lifestyle or reproductive characteristics were
clearly associated with risk of C trachomatis infection.
Conclusions: HPV infected women, particularly women with multiple HPV infections, are at increased risk
of being infected with C trachomatis.
I
nfections with Chlamydia trachomatis, a highly prevalent
sexually transmitted agent worldwide, are mostly asymp-
tomatic (70%–80%) and often remain undetected. Besides
causing cervicitis and urethritis, these infections may result
in serious secondary complications, such as pelvic inflam-
matory disease and pelvic pain (18%–24%), tubal infertility
(6%–21%), and ectopic pregnancy (in 7%–9% of those who
become pregnant).1–5 In addition, C trachomatis has been
suggested to be a cofactor in the development of cervical
cancer.6
In Colombia, the prevalence and determinants of
C trachomatis infection, in particular its association with
HPV infections, have not yet been described.
We report here on the prevalence and determinants on
C trachomatis infection in a large sample from a low income
population in Bogota, Colombia.
PATIENTS AND METHODS
Study population
A prospective cohort study in Bogota, Colombia, was initiated
in the early 1990s by the Colombian National Institute of
Cancer and the International Agency for Research on Cancer
(IARC). The aim of the study was to investigate the natural
history of human papillomavirus (HPV) infections and
cervical intraepithelial neoplasias (CIN) lesions among low
income women.
From November 1993 to November 1995, the Colombian
National Cervical Cancer Institute conducted a census in four
health districts in Bogota, which had no cervical screening
programme previously implemented. Women aged 18–44
years were initially invited to participate. Subsequently, the
upper age limit was expanded to screen elderly women also.
For the study presented here, the first 2000 women
registered in the above census were invited to participate.
They were interviewed face to face by specially trained
interviewers and answered a structured questionnaire on
sociodemographic characteristics, lifelong sexual behaviour,
reproductive history, smoking, and dietary habits. After
interview they were offered a cervical examination, when a
Pap smear was collected, and asked to donate a blood sample.
Only women who had ever been sexually active were
included for this study.
Informed consent was obtained from all participants
included in the study. The local ethics committee and the
ethics committee at IARC cleared the study protocol.
Biological specimens
Cervical scrapes were collected from each woman using two
Ayre spatulas and two endocervical brushes. The first spatula
and brush were used for routine Pap smear, which were
classified according to the Bethesda system. The second
spatula and brush, and the remaining cells of the first spatula
and brush, were placed in a tube containing 5 ml of
phosphate buffered saline (PBS 1X) +0.05% thiomersal.
Cells were detached from the spatula and endocervical brush
by vortexing, and centrifuged at 3000 g for 10 minutes. The
cell pellet was resuspended in 1 ml buffer 10 mM TRIS-HCI
pH 8.3 and stored at 270 C˚ until use. For analysis, a 100 ml
aliquot was boiled for 10 minutes at 100 C˚, cooled on ice, and
centrifuged for 1 minute at 3000 g. 10 ml of this pretreated
crude cell suspension was used for polymerase chain reaction
(PCR) analysis.7 8
In order to assess the quality of the target DNA, a 209 base
pair amplifying b globin PCR was performed using the primer
combination BGPCO3 and BGPCO5 as previously described.9
C trachomatis detection by PCR
The detection of C trachomatis was performed as described
previously.10 Plasmid endogenous specific primers Bio
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PL6.1 (Bio 59-AGAGTACATCGGTCAACGA-39) and PL6.2
(3-TCACAGCGGTTGCTCGAAGCA-5’) were used for PCR
amplification. Briefly, the reaction was carried out in 50 ml
of PCR solution containing 10 mM TRIS-HCl pH 8.3, 50 mM
KCl, 200 mM of each deoxynucleotide, 1.5 mM of MgCl2, 1 U
of DNA polymerase (AmpliTaq; Perkin-Elmer, USA), 25 pmol
of each primer (Eurogentec, Belgium), and 5 ml of sample.
The PCR amplification consisted of DNA denaturation at 95 C˚
for 4 minutes followed by 40 cycles of amplification using a
PE 9600 thermocycler (Perkin-Elmer, USA). Each cycle
included a denaturation step at 95 C˚ for 1 minute, one
annealing step at 55 C˚ for 1 minute, and a chain elongation
step at 72 C˚ for 1.5 minutes. The final elongation step was
extended for another 4 minutes.
The biotinylated PL6.1/PL6.2 PCR products were detected
using an enzyme immunoassay as described previously.11 12
Briefly, in this assay, 5 ml of the biotinylated PCR products
were captured for 1 hour incubation in streptavidin coated
wells of a microtitre plate (Roche, Mannheim, Germany).
Subsequently, the wells were washed three times with 1X
SSC; the captured DNA was denaturated by alkaline
treatment with 0.1 M NaOH, and hybridised for 1 hour
using the digoxigenin labelled type specific probe to PL6.1/
PL6.2 amplified products. The unbound probe was removed
by washing three times with 1X SSC and the hybrids were
detected using an anti-dig Fab framents labelled with
alkaline phosphatase (Roche, Mannheim, Germany) and
paranitrophenyl phosphate (Sigma, USA) was used as
substrate. Finally, the optical density (OD) was measured
at 405 nm using a Labsystem Multiscan reader. In our assay a
cut-off point was defined using three times mean OD of the
negative controls. As a positive control, a 10-fold dilution
series of C trachomatis L2 DNA was used as previously
described,13 resulting in a detection sensitivity corresponding
to 0.01–0.10 inclusion forming units (IFU).
HPV detection by PCR
HPV-DNA detection in these samples had been performed
previously by a standard GP5+/GP6+ PCR-EIA based assay,9
and HPV results for women with cytomorphologically normal
scrapes are presented elsewhere.14 In the present report, HPV
results of abnormal cytology are additionally presented.
Briefly, HPV positives samples were subjected to EIA-HPV
group specific analysis using cocktail probes for high risk
(HR) and low risk (LR) HPVs.11 The HR HPV cocktail probe
consisted of oligoprobes for HPV16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, and 68. The LR HPV consisted of
oligoprobes for HPV 6, 11, 40, 42, 43, 44, HPV82 (MM4),
HPV 83 (MM7), HPV 84 (MM8), Iso39, HPV 71 (CP8061),
CP6108, HPV 81 (CP8304), HPV 26, 34, 53, 54, 55, 57, 61, 70,
72, and 73. However, HPV types with unknown oncogenic
potential—namely, 26, 34, 53, 73, and Iso39—were con-
sidered in the results as HR types. This was based on both
the alignment analysis of the E6 gene (modified from Myers
et al15) and the risk estimates obtained for the various HPV
types within a multicentre case-control study of cervical
cancer conducted by the IARC.16–23 Additionally, HPV
positivity was assessed by Southern blot hybridisation of
GP5+/GP6+ PCR products with the general probe of specific
(a232 P)dCTP labelled DNA fragments from cloned DNA of
HPV 6, 11, 16, 18, 31 and 33.7 9 Samples that were positive by
Southern blot analyses and negative by HR/LR EIA were
considered as HPV X or undetermined type.
Statistical analysis
The association between C trachomatis infections and different
risk factors was evaluated in all women regardless of their
cytological diagnosis. Odds ratios (OR) and 95% confidence
intervals (CI) were calculated using unconditional logistic
regression models, considering C trachomatis infections as a
dependent variable, and several known or hypothesised risk
factors for cervical cancer as independent variables. The
software used for data management and analysis was STATA
(Stata Press, College Station, TX, USA). We performed both
age adjusted (with age grouped as ,25, 25–29, 30–34, 35–44,
45 or more years) and multivariate analyses. The following
variables were included in the multivariate models: age (as
categorised above), educational level (low, education up to
primary level; intermediate, at least half of secondary school
or complete secondary school; and high, technical school or
university), number of lifetime regular (1, 2, 3 or more) and
casual (yes or no) sexual partners, parity (nulliparous, 1–2
children, 3 or more), age first sexual intercourse (,17, 17–19,
20 or more years), oral contraceptive use (ever or never),
condom use, and smoking patterns (ever smoked at least 100
cigarettes). No sample size calculation was done a priori for
this study.
RESULTS
From the 2000 invited women, 53 refused to participate,
seven were considered ineligible (mental illness, hysterect-
omy, history of cervical cancer), 29 did not provide cell
specimens for HPV detection, and 82 had poor DNA quality as
indicated by negative b globin PCR and were therefore
considered inadequate for HPV-PCR and C trachomatis PCR
testing. Thus, a total of 1829 women had PCR and valid HPV
and Chlamydia results. However, for the analysis of char-
acteristics of the studied population we had to further
exclude 16 women who did not answer the questionnaire
completely.
Cytology
All Pap smears were initially classified both using the CIN
classification and the Bethesda System terminology. In all,
1687 women (92.2%) had normal cytological findings
(table 1). Of the 115 women with abnormal cytology, 63
(3.4%) were diagnosed with low grade squamous intrae-
pithelial lesion (LSIL), 28 (1.5%) had atypical squamous cell
of undetermined significance (ASCUS), 14 (0.8%) had atypi-
cal glandular cells of undetermined significance (AGUS),
eight (0.4%) had high grade squamous intraepithelial lesions
(HSIL), and two (0.1%) had invasive cervical cancer.
Table 1 HPV and C trachomatis infections and cytological diagnosis in women from Bogota, Colombia
Cytology
Normal Abnormal Inadequate Any cytology
No % No % No % No %
Total study population 1687 92.2 115 6.3 27 1.5 1829 100.0
HPV positive 229 13.6 45 39.1 3 11.1 277 15.1
C trachomatis positive 85 5.0 6 5.2 1 3.7 92 5.0
% in the population line shows the distribution of cytological diagnosis in the studied population.
% in the HPV and C trachomatis lines show the prevalence of infection in each diagnosis group.
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Characteristics of the studied women
The median age of women participating in the study was 33
years (range 18–85 years). Most women had low (38.0%) or
intermediate (36.9%) educational level, had their first sexual
intercourse or first regular sexual partner before the age of 20
(62.2%), reported only one lifelong sexual partner (74.0%),
and had at least two full term pregnancies (median 2). IUD
was the most common contraceptive method ever used
(59.1%), followed by oral contraceptives (49.9%) and
condoms (31.6%). Less than one third (28.3%) had ever
smoked regularly (table 2).
C trachomatis prevalence and risk factors
The overall prevalence of C trachomatis infection was 5.0%,
and did not differ substantially between women with normal
or abnormal cytological results (table 1).
The highest prevalence of C trachomatis was observed in
women aged 30–34 years (7.9%) and the lowest in women
older than 45 years (1.5%) (table 2; fig 1).
Table 2 Determinants of C trachomatis infection in women from Bogota, Colombia
Total number of
women
(n = 1813)*
Women infected
with
C trachomatis
OR OR`No % No %
Age (y)
,25 293 16.2 19 6.5 1.7 (0.87 to 3.1) 1.6 (0.7 to 3.5)
25–29 360 19.9 14 3.9 1.0 (0.5 to 1.9) 0.8 (0.4 to 1.8)
30–34 433 23.9 34 7.9 2.0 (1.2 to 3.6) 1.8 (0.98 to 3.2)
35–44 522 28.8 21 4.0 1 1
45+ 205 11.3 3 1.5 0.4 (0.1 to 1.2) 0.2 (0.06 to 1.1)
Education
None/low 689 38.0 31 4.5 1 1
Intermediate 668 36.9 30 4.5 0.8 (0.4 to 1.3) 0.8 (0.4 to 1.4)
High 455 25.1 30 6.6 1.3 (0.7 to 2.0) 1.2 (0.7 to 2.5)
Missing 1 0.06 0 0.0
Age at 1st sexual
intercourse (y)
>20 686 37.8 27 3.9 1 1
17–19 633 34.9 39 6.2 1.5 (0.92 to 2.6) 1.3 (0.8 to 2.3)
(16 494 27.3 25 5.1 1.3 (0.7 to 2.2) 1.3 (0.6 to 2.4)
Lifetime number of
regular sexual partners1
1 1341 74.0 66 4.9 1 1
2 309 17.0 14 4.5 0.9 (0.5 to 1.7) 0.9 (0.5 to 1.6)
3 62 3.4 3 4.8 1.1 (0.3 to 3.7) 1.0 (0.3 to 3.3)
Missing 101 5.6 8 7.9
Ever had a casual sexual
partner
No 1302 71.8 61 4.7 1 1
Yes 428 23.6 23 5.4 1.1 (0.7 to 1.8) 1.0 (0.6 to 1.8)
Missing 83 4.6 7 8.4
Parity
0 115 6.3 6 5.2 1 1
1–2 944 52.1 52 5.5 1.1 (0.4 to 2.6) 1.5 (0.5 to 4.4)
>3 754 41.6 33 4.4 1.0 (0.4 to 2.6) 1.5 (0.5 to 5.0)
Oral contraceptives
Never used 886 48.9 48 5.4 1 1
Former user 741 40.9 30 4.1 0.7 (0.4 to 1.2) 0.7 (0.4 to 1.2)
Current user 163 9.0 12 7.4 1.2 (0.6 to 2.3) 1.4 (0.7 to 2.7)
Missing 23 1.3 1 4.4
Duration of oral
contraceptive use
,3 years 544 30.0 21 3.9 0.7 (0.4 to 1.1) 0.7 (0.4 to 1.2)
>3 years 287 15.8 17 5.9 1.1 (0.6 to 2.0) 1.2 (0.6 to 2.1)
Missing duration 73 4.0 4 5.5
IUD
Never used 710 39.2 36 5.1 1 1
Former user 572 31.6 29 5.1 1.0 (0.6 to 1.7) 1.1 (0.6 to 1.8)
Current user 500 27.6 26 5.2 0.9 (0.5 to 1.5) 0.9 (0.5 to 1.5)
Missing 31 1.7 0 0.0
Condom
Never 1212 66.9 59 4.9 1 1
Ever 572 31.6 32 5.6 1.1 (0.7 to 1.7) 1.0 (0.7 to 1.9)
Missing 29 1.6 0 0.0
Smoking
Never 1300 71.7 61 4.7 1 1
Former smoker 215 11.9 10 4.7 1.1 (0.5 to 2.2) 1.1 (0.6 to 2.3)
Current smoker 298 16.4 20 6.7 1.4 (0.8 to 2.4) 1.1 (0.6 to 2.1)
*1843 women with complete questionnaire information and C trachomatis detection; 16 women who did not fill in
completely the questionnaire were excluded.
OR = odds ratio adjusted for age.
`OR = odds ratio adjusted for age, education, number of regular partners, casual partners, parity, age at first
sexual intercourse, use of oral contraceptives and condom, and smoking habit.
1Defined as sexual partners in relationships lasting at least 6 months.
Defined as sexual partners in relationships lasting less than 6 months.
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There was no clear association between educational level,
sexual behaviour (number of regular or casual sexual
partners), reproductive history (parity, ever use or duration
of use of oral contraceptives, use of condoms or IUD), or
smoking patterns and risk of C trachomatis infection (table 2).
HPV prevalence
The overall HPV DNA prevalence was 15.1%. Women
presenting abnormal cytology had a substantially higher
prevalence of HPV infections (39.1%) than women with
normal cytology (13.6%) (table 1).
There were more women infected with HR HPV types
(11.9%) than with LR types (2.9%). Infections with unchar-
acterised types (HPV X, 0.5%) were few (table 3).
Association between C trachomatis and HPV
infections
The prevalence of C trachomatis infections was non-signifi-
cantly higher among women infected with HPV of any
studied type than among HPV uninfected women (6.9% v
4.7%; adjusted OR 1.3, 95% CI: 0.8 to 2.4). C trachomatis
prevalence was higher among women with multiple HPV
infections (9.5%) than women with single HPV infections
(5.9%; adjusted OR 2.5, 95% CI: 1.1 to 5.9) (table 3).
DISCUSSION
This is the first study describing the prevalence and
determinants of C trachomatis infections in the population of
Bogota, Colombia.
The overall C trachomatis prevalence in this study (5.0%)
was similar to the prevalence reported in women from the
general population in Amsterdam, Colorado, Washington,
and Copenhagen, which ranged from 4.5% to 9%.12 24–26 Our
results also confirm a somewhat higher C trachomatis
infection prevalence in young age groups, as observed in
other populations.12 27 Behavioural factors (such as early age
in the initiation of sexual activity, multiple partners, irregular
use of condoms, use of contraceptive methods) were,
unexpectedly, not associated with C trachomatis infection
risk. Thus, our study is in partial disagreement with some
previous reports,12 25 28 29 which found associations with
C trachomatis infection and oral contraceptive use, parity,
lifetime number of sexual partners, and smoking habits.
Discrepancies between our results and those from studies
conducted elsewhere may be because of differences in the
characteristics of the studied populations (such as age,
patterns of sexual behaviour or openess in reporting sexual
behaviour), and variations in the sensitivity and specificity of
laboratory methods used.
Duration of oral contraceptive use had no apparent
influence on the prevalence of C trachomatis infection—as
reported also by Munk et al12 and Jacobson et al.30 The lack of
association between parity and C trachomatis infection
observed by us is in line with the study by Munk et al12 but
it contrasts with the study by Bagshaw et al.31
Besides young age, the only risk factor independently
associated with C trachomatis infection in our study was HPV
infection, particularly multiple infections. This is in agree-
ment with some previous studies using PCR and serological
assays.32 33 The clear association between C trachomatis and
multiple HPV infections might be indicative of multiplicity of
sexual partners from women themselves or their partners.
The male partner(s) sexual practices (such as multiplicity of
sexual partners or high risk sexual behaviour) is a plausible
explanation for C trachomatis infection among women. Such
information is, however, not available in our study.
Some studies reported an association between antibodies
to C trachomatis and SIL lesions.34–37 However, analysis of
the DNA presence of C trachomatis and its association with
HPV infections and SIL lesions is still limited. We did not
observe any substantial difference in C trachomatis infection
prevalence between women with normal or abnormal cervical
cytology. This suggests that C trachomatis does not itself
induce cervical abnormalities. The role of C trachomatis as a
potential cofactor in cervical disease, however, cannot be
ruled out.
Figure 1 Prevalence and 95% CI of C trachomatis and HPV DNA in
women from Bogota, Colombia.
Table 3 C trachomatis infection and HPV infection in women from Bogota, Colombia
Total number of
women
(n = 1813)*
Women infected
with C trachomatis
OR OR`No % No %
HPV negative
(uninfected)
1536 84.7 72 4.7 1 1
HPV positive (any type) 277 15.3 19 6.9 1.3 (0.8 to 2.3) 1.3 (0.8 to 2.4)
HPV types1
High risk 16 11.9 14 6.5 1.2 (0.7 to 2.3) 1.3 (0.7 to 2.4)
Low risk 52 2.9 3 5.8 1.1 (0.3 to 3.8) 0.9 (0.2 to 3.8)
HPV X 9 0.5 2 22.2 4.6 (0.9 to 23.0) 4.6 (0.9 to 24.2)
Single infection 203 11.2 12 5.9 1.1 (0.6 to 2.1) 1.0 (0.5 to 2.0)
Multiple infections 74 4.1 7 9.5 2.0 (0.9 to 4.6) 2.5 (1.1 to 5.9)
*1843 women with complete questionnaire information and C trachomatis detection; 16 women who did not fill in
completely the questionnaire were excluded.
OR = odds ratio adjusted for age.
`OR = odds ratio adjusted for age, education, number of regular partners, casual partners, parity, age at first
sexual intercourse, use of oral contraceptives and condom, and smoking habit.
1High risk (HR) types: 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, ISO39, 73. Low risk
(LR) types: 6, 11, 40, 42, 43, 44, MM4, MM7, MM8, CP8061, CP6108, CP 8304, 54, 55, 57, 61, 70, 72.
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Key messages
N C trachomatis infection is relatively common (about 5%
prevalence) among adult women in Bogota, Colombia.
N HPV infected women, particularly women with multiple
HPV infections, are at increased risk of being infected
with C trachomatis.
N The overall prevalence of C trachomatis does not seem
to differ substantially between women with normal and
those with abnormal cervical cytology.
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